Peripheral Neuropathy Treatment Market Applications and Competitive Landscape By 2027
Peripheral Neuropathy Market Overview
According to MRFR analysis, Peripheral Neuropathy Market is
expected to register a CAGR of 3.9% during the forecast period
of 2019 to 2025 and is expected to reach USD 292.40
Million by 2025.
Peripheral neuropathy develops when nerves in the body's extremities,
such as the hands, feet, and arms, are damaged. The symptoms depend on which
nerves are affected.
The growth of the global peripheral
neuropathy market is driven by various factors, such as increasing
chemotherapy treatments for cancer and growing awareness about peripheral
neuropathy. Additionally, rising innovations in the field of peripheral
neuropathy by top players are also driving the market. However, stringent
government regulations are projected to hamper the growth of the global
peripheral neuropathy market.
Several market players currently dominate the global peripheral
neuropathy market. The key players are involved in product launches and
strategic collaborations to strengthen their market positions. For example, in
June 2015, Spinifex Pharmaceuticals acquired by Novartis. The acquisition was
centered on Spinifex's EMA401, a new drug that could offer relief from chronic
neuropathic pain. This acquisition helps Novartis to be a prominent player in
the peripheral neuropathy market by expanding the market.
Request Free Sample Copy at:
https://www.marketresearchfuture.com/sample_request/8485
Regional Analysis
The market has been divided, by region, into the Americas, Europe,
Asia-Pacific, and the Middle East & Africa. The Americas are expected to be
the largest market owing to the rising per capita healthcare expenditure. The
peripheral neuropathy market in the Americas has further been branched into
North America and Latin America, with the North American market divided into
the US and Canada. The European peripheral neuropathy market has been
categorized as Western Europe and Eastern Europe. The Western European market
has further been classified as Germany, France, the UK, Italy, Spain, and the
rest of Western Europe. The peripheral neuropathy market in Asia-Pacific has
been segmented into Japan, China, India, South Korea, Australia, and the rest
of Asia-Pacific. Due to the rising geriatric population and the growing
prevalence of diabetes, Asia-Pacific is expected to be the fastest-growing. The
peripheral neuropathy market in the Middle East & Africa has been divided
into the Middle East and Africa.
Segmentation
The Global Peripheral Neuropathy Market has been segmented based on
type, treatment, and end user.
The market, based on type, has been divided into diabetic peripheral
neuropathy (DPN), chemotherapy-induced peripheral neuropathy (CIPN), idiopathic
peripheral neuropathy, and HIV/AIDS-associated peripheral neuropathy.
The diabetic peripheral neuropathy (DPN)segment is likely to be the
largest during the review period due to their increasing prevalence of diabetic
peripheral neuropathy in youth with diabetes.
The chemotherapy-induced peripheral neuropathy (CIPN) segment is
predicted to be the fastest-growing due to increasing chemotherapy for the
treatments of cancer patients. Many market players come up with different
treatment methods and devices with advanced technologies. For instance, in June
2019, RxFunction launched sensory prosthesis for people with peripheral
neuropathy.
The global peripheral neuropathy market has been segregated, on the
basis of treatment, into pharmacological therapies, non-pharmacological therapies, and others.
The pharmacological therapies segment is expected to hold the majority
share of the market owing to the pharmacological therapies are primary in the
treatment of peripheral neuropathy. The non-pharmacological therapies segment
is expected to be the fastest-growing due to the as non-pharmacological
therapies are used along with other treatment options for neurotherapy.
The end users of the market are hospitals and clinics, ambulatory centers, and
others. The hospitals and clinics segment is expected to hold the largest share
of the market due to the rising awareness about advanced treatments available
in the hospitals and expertise. The ambulatory centers segment is expected to
be the fastest growing owing to the availability of specialized medical
services and advanced medical technology
Key Players
Some of the key players in the Global Peripheral Neuropathy Market
are Abbott Laboratories (US), Bristol Myers Squibb (US), Novartis AG
(UK), Eli Lilly and Company (US), Pfizer Inc (US), GlaxoSmithKline plc (UK),
Merck and Co. Inc. (US), Cipla Limited (India), Lupin Limited (India), Dr.
Reddy's Laboratories (India), F. Hoffmann-La Roche Ltd. (UK), RxFunction, Inc.
(US) among others
Browse Detailed TOC with COVID-19 Impact Analysis at:
https://www.marketresearchfuture.com/reports/peripheral-neuropathy-market-8485
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the
complexity of various industries through our Cooked Research Report (CRR),
Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have
supreme objective to provide the optimum quality market research and
intelligence services to our clients.
Contact us:
Market Research Future (part of Wantstats Research and Media Private
Limited),
99 Hudson Street, 5Th Floor,
New York, New York 10013
United States of America
+1 646 845 9312
Email: sales@marketresearchfuture.com
Comments
Post a Comment